On October 12, at the 2026 Annual Meeting of the American Society for Bone & Mineral Research (ASBMR), in a late-breaking oral session, Regeneron presented positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with FOP.

The results show sustained efficacy of Pasatru, including no new bone growth and significantly reduced flare-ups, and a consistent safety profile from weeks 56 to 84, supporting long-term disease control.

We are grateful to the 63 people with FOP ages 18+ from around the world who enrolled in the Phase 3 OPTIMA Trial.

Read Regeneron's press release about the ASBMR late-breaking oral session